Marine Depsipeptide Nobilamide I Inhibits Cancer Cell Motility and Tumorigenicity via Suppressing Epithelial-Mesenchymal Transition and MMP2/9 Expression.

Authors :: Le TC
Pulat S
Lee J
Kim GJ
Kim H
Lee EY
Hillman PF
Choi H
Yang I
Oh DC
Kim H
Nam SJ
Fenical W
Source :: ACS omega [ACS Omega] 2022 Jan 03; Vol. 7 (2), pp. 1722-1732. Date of Electronic Publication: 2022 Jan 03 (Print Publication: 2022).
Publication Year :: 2022
Abstract: A cyclic depsipeptide, nobilamide I ( 1 ), along with the known peptide A-3302-B/TL-119 ( 2 ), was isolated from the saline cultivation of the marine-derived bacterium Saccharomonospora sp., strain CNQ-490. The planar structure of 1 was elucidated by interpretation of 1D and 2D NMR and MS spectroscopic data. The absolute configurations of the amino acids in 1 were assigned by using the C <subscript>3</subscript> Marfey's analysis and comparing them with those of 2 based on their biosynthetic pathways. Nobilamide I ( 1 ) decreased cell motility by inhibiting epithelial-mesenchymal transition markers in A549 (lung cancer), AGS (gastric cancer), and Caco2 (colorectal cancer) cell lines. In addition, 1 modulated the expression of the matrix metalloproteinase (MMP) family (MMP2 and MMP9) in the three cell lines.<br />Competing Interests: The authors declare no competing financial interest.<br /> (© 2022 The Authors. Published by American Chemical Society.)

Full Text Access

Tools